Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients
Patient input into the design of pragmatic trials may otpimize patient accrual and retention.
Why this item may be useful
Physicians and patients were surveyed to assess interest and willingness to participate in pragmatically designed clinical trials incorporating novel methodologies that might help ensure rapid accrual. When questioned regarding whether patients would prefer a shorter more intense regimen verses a longer regimen with fewer side effects, the majority of responders preferred the later. Patients were also willing to join trials if the administrative processes around trial entery and participation were streamlined.
This institution uses the information from patient and physician surveys as part of a wide reaching program of pragmatic clinical trials called REthinking Clinical Trials (REaCT). The goal is to design randomized trials of appropriate size but with pragmatic endpoints that will lead to clinical practice changes.